Back to search
BRAF or NRAS Mutant Metastatic Melanoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which BRAF or NRAS Mutant Metastatic Melanoma trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which BRAF or NRAS Mutant Metastatic Melanoma trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma
This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with…
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous…